The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

被引：0
|
作者：
Yang, Ping [1 ]
Liu, Shuozi [1 ]
Zhang, Weilong [1 ]
Wang, Jing [1 ]
Chen, Yingtong [1 ]
Jing, Hongmei [1 ]
机构：
[1] Peking Univ Third Hosp, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184372
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Possible Role of Platelet-Rich Plasma in the Treatment of Patients with Postherpetic Neuralgia: A Prospective, Single-Arm, Open-Label Clinical Study
    Abu El-Hamd, Mohammed
    Abd Elaa, Shereen G.
    Abdelwahab, Ashraf
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2024, 15 (06) : 986 - 991
  • [42] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [43] Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter Open-Label, Single-Arm, Phase II Trial
    Gine, Eva
    de la Cruz, Fatima
    Jimenez Ubieto, Ana
    Lopez Jimenez, Javier
    Martin Garcia-Sancho, Alejandro
    Jose Terol, M.
    Gonzalez Barca, Eva
    Casanova, Maria
    de la Fuente, Adolfo
    Marin-Niebla, Ana
    Muntanola, Ana
    Jose Gonzalez-Lopez, Tomas
    Aymerich, Marta
    Setoain, Xavier
    Cortes-Romera, Montserrat
    Rotger, Amanda
    Rodriguez, Sonia
    Medina Herrera, Alejandro
    Garcia Sanz, Ramon
    Nadeu, Ferran
    Bea, Silvia
    Campo, Elias
    Lopez-Guillermo, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (11) : 1196 - +
  • [44] Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
    Kumar, Anita
    Soumerai, Jacob D.
    Abramson, Jeremy S.
    Batlevi, Connie Lee
    Chadha, Puja
    Dogan, Ahmet
    Falchi, Lorenzo
    Flaherty, Kelsey
    Friedman, Chaya
    Grieve, Clare
    Ho, Caleb
    Johnson, P. Connor
    Joseph, Ashlee
    Khan, Niloufer
    Mi, Joanna
    Martignetti, Rosalba
    Matasar, Matthew J.
    Owens, Colette
    Ruiters, Jade
    Sechio, Sidney
    Seshan, Venkatraman
    Simkins, Elizabeth
    Abdel-Wahab, Omar
    Zelenetz, Andrew D.
    BLOOD, 2021, 138
  • [45] Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
    Leger, Jean-Marc
    De Bleecker, Jan L.
    Sommer, Claudia
    Robberecht, Wim
    Saarela, Mika
    Kamienowski, Jerzy
    Stelmasiak, Zbigniew
    Mielke, Orell
    Tackenberg, Bjoern
    Shebl, Amgad
    Bauhofer, Artur
    Zenker, Othmar
    Merkies, Ingemar S. J.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 (02) : 130 - 140
  • [46] Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
    Dane, Faysal
    Ozgurdal, Kirhan
    Yalcin, Suayib
    Benekli, Mustafa
    Aykan, Nuri Faruk
    Yucel, Idris
    Ozkan, Metin
    Evrensel, Turkkan
    Sevinc, Alper
    Coskun, Hasan Senol
    Sanli, Ulus Ali
    Kara, Ismail Oguz
    Yumuk, Perran Fulden
    BMJ OPEN, 2020, 10 (03):
  • [47] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study
    Bai, Xueli
    Chen, Yiwen
    Zhang, Junlei
    Hu, Wendi
    Li, Xiang
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [49] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
    Xie, Y.
    Mi, L.
    Zheng, W.
    Ping, L.
    Lin, N.
    Tu, M.
    Zhang, C.
    Ying, Z.
    Liu, W.
    Deng, L.
    Wu, M.
    Wang, X.
    Zhu, J.
    Song, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
12345